Table 3 Disease-free survival and overall survival stratified by stage
| Â | Arm A IRI+LV+5FU | Arm B LV+5FU | P(log-rank) |
|---|---|---|---|
Stage B (n = 425) | Â | Â | Â |
Disease-free survival (DFS) | Â | Â | 0.561 |
   Progressions, n (%) | 36 (16.8) | 35 (16.6) |  |
   Median (months) | Not reached yet | Not reached yet |  |
   three-year DFS (%) | 86 | 83 |  |
   five-year DFS (%) | 79 | 78 |  |
   seven-year DFS (%) | 75 | 73 |  |
Overall survival (OS) | Â | Â | 0.389 |
   Deaths, n (%) | 39 (18.2) | 46 (21.8) |  |
   Median (months) | Not reached yet | Not reached yet |  |
   three-year OS (%) | 93 | 89 |  |
   five-year OS (%) | 86 | 83 |  |
   seven-year OS (%) | 80 | 78 |  |
Stage C (n = 448) | Â | Â | Â |
Disease-free survival (DFS) | Â | Â | 0.515 |
   Progressions, n (%) | 74 (32.6) | 77 (34.8) |  |
   Median (months) | 106 | 104 |  |
   three-year DFS (%) | 69 | 68 |  |
   five-year DFS (%) | 60 | 57 |  |
   seven-year DFS (%) | 57 | 52 |  |
Overall survival (OS) | Â | Â | 0.539 |
   Deaths, n (%) | 79 (34.8) | 82 (37.1) |  |
   Median (months) | Not reached yet | Not reached yet |  |
   three-year OS (%) | 83 | 83 |  |
   five-year OS (%) | 71 | 68 |  |
   seven-year OS (%) | 64 | 59 |  |